At its meeting on 15 May 2023, the Transparency Council adopted Position No. 51/2023 on the evaluation of Forxiga (dapagliflozin) for the indication: adult patients diagnosed with chronic kidney disease, with eGFR <60ml/min/1.73 m2, with albuminuria or proteinuria, treated with ACE-i/ARB-based therapy for not less than four weeks or with contraindications to these therapies.